Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
11 p, 832.5 KB Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer : Data from the Prostate Cancer Registry / Bjartell, Anders (Lund University. Department of Translational Medicine, Medical Faculty) ; Lumen, Nicolaas (Universitair Ziekenhuis Gent) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Paiss, Thomas (Urologie team Ulm, Ulm, Germany) ; Gomez-Veiga, Francisco (Instituto de Investigación Biomédica de Salamanca) ; Birtle, Alison (Royal Preston Hospital) ; Kramer, Gero (Medical University of Vienna. Department of Urology) ; Kalinka, Ewa (Polish Mother's Memorial Hospital, Research Institute. Clinic of Oncology) ; Spaëth, Dominique (Centre d'Oncologie de Gentilly, Nancy, France) ; Feyerabend, Susan (Studienpraxis Urologie, Nürtingen, Germany) ; Matveev, Vsevolod (N.N. Blokhin National Cancer Research Center) ; Lefresne, Florence (Janssen Pharmaceutica N.V.. EMEA Oncology) ; Lukac, Martin (Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V) ; Wapenaar, Robert (Janssen-Cilag B.V., Breda, The Netherlands) ; Costa, Luis (Universidade de Lisboa. Oncology Division, Faculdade de Medicina, Hospital de Santa Maria, Instituto de Medicina Molecular) ; Chowdhury, Simon (Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona
Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate cancer (mCRPC) necessitates additional treatments. [...]
2021 - 10.1007/s11523-021-00807-4
Targeted Oncology, Vol. 16 (april 2021) , p. 357-367  
2.
15 p, 623.6 KB Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer : The Prostate Cancer Registry / Chowdhury, Simon (Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute) ; Bjartell, Anders (Skåne University Hospital (Suècia)) ; Lumen, Nicolaas (Universitair Ziekenhuis Gent) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Paiss, Thomas (Urologie Team Ulm, Ulm, Germany) ; Gomez-Veiga, Francisco (Instituto de Investigación Biomédica de Salamanca) ; Birtle, Alison (Royal Preston Hospital) ; Kramer, Gero (Medical University of Vienna. Department of Urology) ; Kalinka, Ewa (Polish Mother's Memorial Hospital-Research Institute. Clinic of Oncology) ; Spaëth, Dominique (Centre d'Oncologie de Gentilly, Nancy, France) ; Feyerabend, Susan (Studienpraxis Urologie, Nürtingen, Germany) ; Matveev, Vsevolod (N.N. Blokhin National Cancer Research Center) ; Lefresne, Florence (EMEA Oncology, Janssen Pharmaceutica N.V., Beerse, Belgium) ; Lukac, Martin (Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V) ; Wapenaar, Robert (Janssen-Cilag B.V., Breda, the Netherlands) ; Costa, Luis (Universidade de Lisboa. Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculdade de Medicina)
Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials. [...]
2020 - 10.1007/s11523-020-00720-2
Targeted Oncology, Vol. 15 (june 2020) , p. 301-315  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.